Search Results | DrugBank Online

Displaying drugs 14076 - 14100 of 14521 in total

OSI-7904L

OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.

Investigational

Matched Description: … liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and …

5-{[(4-AMINO-3-CHLORO-5-FLUOROPHENYL)SULFONYL]AMINO}-1,3,4-THIADIAZOLE-2-SULFONAMIDE

Experimental

4-(6-{[(1R)-1-(hydroxymethyl)propyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzoic acid

Experimental

4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol

Experimental

3-[6-bromo-2-fluoro-3-(1H-pyrazolo[3,4-c]pyridazin-3-ylmethyl)phenoxy]-5-chlorobenzonitrile

Experimental

AZD-6280

AZD6280 has been used in trials studying the basic science of Anxiety.

Investigational

Seladelpar

Seladelpar (MBX-8025) has been used in trials studying the treatment of Hyperlipidemia.

Investigational

REP8839

REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).

Investigational